Lataa...
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001
Targeted cancer therapeutics can be effective when patients are preselected to maximize the chance of response. Increasingly, molecular markers such as oncogenic DNA mutations are being exploited to help guide patient preselection. These DNA lesions can predict for either a positive or negative resp...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Clinical Investigation
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2912204/ https://ncbi.nlm.nih.gov/pubmed/20664174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI44026 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|